NCT02307162View on ClinicalTrials.gov

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Inflammatory Disorder of the Respiratory TractChronic Obstructive Pulmonary Disorder
Interventions
DRUG

RPL554

Phosphodiesterase 3 and 4 Inhibitor

DRUG

Placebo

Dummy solution

Trial Locations (1)

M23 9QP

Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

Verona Pharma plc

INDUSTRY

NCT02307162 - SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects | Biotech Hunter | Biotech Hunter